Semprex D

PATIENT INFORMATION

Patients taking SEMPREX-D (acrivastine and pseudoephedrine) Capsules should receive the
following information. SEMPREX-D (acrivastine and pseudoephedrine) Capsules are prescribed to reduce symptoms associated
with seasonal allergic rhinitis. Patients should be instructed to take
SEMPREX-D (acrivastine and pseudoephedrine) Capsules only as prescribed and not to exceed the prescribed dose.
Patients should be advised against the concurrent use of SEMPREX-D (acrivastine and pseudoephedrine) with
over-the-counterantihistamines and decongestants. Patients who are or may
become pregnant should be told that this product should be used in pregnancy or
during lactation only if the potential benefit justifies the potential risks to
the fetus or nursinginfant. Due to the risk of hypertensive crisis, patients
should be instructed not to take SEMPREX-D (acrivastine and pseudoephedrine) Capsules (acrivastine and
pseudoephedrine hydrochloride) if they are presently taking a monoamine oxidase
inhibitor or for 14 days after stopping use of an MAO inhibitor. Patients should
be advised to assess their individual responses to SEMPREX-D (acrivastine and pseudoephedrine) Capsules before
engaging in any activity requiring mental alertness, such as driving a car or
operating machinery. Patients should be advised that the concurrent use of
SEMPREX-D (acrivastine and pseudoephedrine) Capsules with alcohol and other CNS depressants may lead to
additional reductions in alertness and impairment of CNS performance and should
be avoided.

Last reviewed on RxList: 5/20/2009
This monograph has been modified to include the generic and brand name in many instances.